🇺🇸💊🏠Gilead Unveils $11B U.S. Investment Boost Amid Trump Tariff Pressure
🔹 Summary:
Gilead Sciences announced an additional $11 billion investment in U.S. manufacturing and research, responding to Trump administration tariff pressures and bringing its total domestic commitment to $32 billion through 2030.
The move aligns Gilead with peers like Eli Lilly, Johnson & Johnson, and Merck, which are also ramping up U.S. production amid looming import levies.
🔹 Key Points:
• Gilead’s new funding will build three new facilities and upgrade three existing sites.
• The total U.S. manufacturing and R&D investment plan now stands at $32B through 2030.
• Trump’s tariff policies and import probes have intensified pressure on U.S. pharma companies.
• Major drugmakers are reshoring production to mitigate supply chain and tariff risks.
• The sector braces for potential levies targeting pharmaceutical imports.
@CMEActiveTrader Tickers Of Interest: $ES $NQ $YM $XLV $IBB
Tickers Of Interest: $GILD $LLY $JNJ $MRK $PFE $BMY $AMGN $USD $DXY $SPY $QQQ $XPH $XBI
3.39K
2
The content on this page is provided by third parties. Unless otherwise stated, OKX is not the author of the cited article(s) and does not claim any copyright in the materials. The content is provided for informational purposes only and does not represent the views of OKX. It is not intended to be an endorsement of any kind and should not be considered investment advice or a solicitation to buy or sell digital assets. To the extent generative AI is utilized to provide summaries or other information, such AI generated content may be inaccurate or inconsistent. Please read the linked article for more details and information. OKX is not responsible for content hosted on third party sites. Digital asset holdings, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition.